Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10281335 | 0.98 | S1PR1 (0.41) | S1PR1THRATHRBSPHK2MEN1 | |
| SCHEMBL81798 | 0.90 | KLK7 (0.34) | S1PR1S1PR4S1PR5CNR2CREBBP | |
| SCHEMBL81833 | 0.89 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL13851953 | 0.87 | S1PR1 (0.52) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL12337608 | 0.84 | S1PR1 (0.55) | S1PR1THRATHRBSPHK2MEN1 | |
| SCHEMBL2469156 | 0.82 | S1PR1 (0.53) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL13665155 | 0.79 | S1PR1 (0.60) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL13664785 | 0.78 | S1PR1 (0.64) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL2464915 | 0.78 | S1PR1 (0.64) | S1PR1THRATHRBS1PR4S1PR5 | |
| SCHEMBL79819 | 0.78 | S1PR1 (0.40) | S1PR1KMT2AS1PR4S1PR5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-1961734-B1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | S1PR1 370/4885THRA 705/4885THRB 536/4885 |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | HRH3, HRH2, HRH4 | S1PR1 370/4885THRA 705/4885THRB 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.